A study evaluating the efficacy and safety of Dihydroartemisinine-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria, and chloroquine for plasmodium vivax in Homalin (Sagaing Division), Lashio (Shan State) and Bokepyin (Tanintharyi Division)

Clinical Research Unit (malaria), Defense Services General Hospital0 sites200 target enrollmentFebruary 28, 2014

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Not specified
Sponsor: Clinical Research Unit (malaria), Defense Services General Hospital
Enrollment: 200
Status: Recruiting
Last Updated: 6 years ago

No summary available.

Registry

who.int

Start Date

February 28, 2014

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

Clinical Research Unit (malaria), Defense Services General Hospital

•age above 13 years inclusive and above except females aged 13\-17 year old inclusive;
•\- mono\-infection with P. falciparum detected by microscopy (parasitaemia of 500\-100,000/micro litre asexual forms) or P. vivax detected by microscopy (parasitaemia greater than 250/micro litre asexual forms);
•\- presence of axillary equal to 37\.5 degrees celsius or history of fever during the past 24 h;
•\- ability to swallow oral medication;
•\- ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
•\- informed consent from the patient or from a parent or guardian in the case of children

•\- presence signs of severe falciparum malaria according to the definitions of WHO;
•\- mixed or mono\-infection with another Plasmodium species detected by microscopy;
•\- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
•\- regular medication, which may interfere with antimalarial pharmacokinetics;
•\- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
•\- a positive pregnancy test or breastfeeding;
•\- unable to or unwilling to take a pregnancy test or contraceptives.